Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication ...

As a result, commercial teams are evolving as valuable partners to HCPs. From educating key experts before launch and ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure ...

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...

Welcome to the second edition of the new Changing Faces Board round-up. The pharmaceutical sector saw a wave of significant ...

A new partnership has been set up between the Ella Dawson Foundation, a UK-based charity for young people with cancer, and ...

In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk ...